Open-label Phase II pilot (n=20) testing feasibility, safety and preliminary efficacy of high-intensity inpatient MDMA-assisted psychotherapy for treatment-refractory PTSD; two MDMA sessions (80+40 mg; 120+60 mg) integrated into a four-week inpatient programme with manualised preparatory and integrative therapy.
This open-label pilot evaluates a high-intensity inpatient delivery of manualised MDMA-assisted psychotherapy for adults with treatment-refractory PTSD, integrating two MDMA sessions within a four-week inpatient programme at ARQ Centre'45.
Two experimental MDMA sessions (Session 1: 80 mg plus 40 mg supplemental; Session 2: 120 mg plus 60 mg supplemental) are combined with non-drug preparatory and integrative therapy; outcomes include feasibility, safety, and PTSD symptom change.
High-intensity inpatient MDMA-assisted psychotherapy integrated into a four-week programme.
Session 1: 80 mg MDMA HCl followed by supplemental 40 mg; Session 2: 120 mg MDMA HCl followed by supplemental 60 mg; manualised psychotherapy integrated.